Drug intelligence / Profile preview

SC661

Development stage: Preclinical
Lead developer: Se-cure Pharmaceuticals
Modality: Small Molecules

Overview

SC661 is a preclinical-stage botanical complex derived from the soybean plant, developed by Se-cure Pharmaceuticals. It is specifically designed to accelerate dental bone rejuvenation, aiming to shorten the recovery period required for dental implant procedures. By encouraging the formation of a robust bone basis in the jaw, SC661 serves as a recovery management strategy for dentists preparing patients for implants. The drug is developed following US FDA botanical drug development guidelines for botanical drug candidates.

Beyond the preview

Go deeper on SC661.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC661.

Explore the full profile